MY195045A - Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer - Google Patents

Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer

Info

Publication number
MY195045A
MY195045A MYPI2016002278A MYPI2016002278A MY195045A MY 195045 A MY195045 A MY 195045A MY PI2016002278 A MYPI2016002278 A MY PI2016002278A MY PI2016002278 A MYPI2016002278 A MY PI2016002278A MY 195045 A MY195045 A MY 195045A
Authority
MY
Malaysia
Prior art keywords
liver cancer
tumour
liver
auto
tumour antigens
Prior art date
Application number
MYPI2016002278A
Inventor
Cornelia Wing Yin Man
Norman Fung Man Wai
Bing Lou Wong
Benjamin Chi Yin Wai
Original Assignee
Dragon Victory Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Application filed by Dragon Victory Dev Ltd filed Critical Dragon Victory Dev Ltd
Publication of MY195045A publication Critical patent/MY195045A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Cells within liver tumour mass comprise a unique set of proteins/tumour antigens when compared to the nonnal liver tissues epithelial cells juxtaposed to the tumour. The presence of tumour antigens couples the production of auto-antibodies against these tumour antigens. The present invention relates to the identification and elucidation of a protein set that can act as a novel marker set for liver cancer diagnosis and prognosis. Specifically, it relates to a kit that enables diagnostic and prognostic measurement of auto-antibodies in serum of liver cancer patients. The present invention provides a non- invasive, specific, sensitive, and cost effective detection and quantification method by evaluating a set of validated liver cancer proteins/tumourantigens, which includes Bmi- 1, VCCI, SUM0-4, RhoA, TXN, ET-1, UBE2C, HDGF2, FGF21, LECT2, SOD 1, STMN4, Midkine, fL-17 A or IL26, to complement the conventional diagnostic methods.
MYPI2016002278A 2014-07-02 2014-07-31 Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer MY195045A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
PCT/US2014/049038 WO2016003479A1 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (1)

Publication Number Publication Date
MY195045A true MY195045A (en) 2023-01-04

Family

ID=55019816

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2016002278A MY195045A (en) 2014-07-02 2014-07-31 Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
MYPI2017001446A MY179845A (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2017001446A MY179845A (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Country Status (12)

Country Link
EP (1) EP3164711A4 (en)
JP (2) JP2017520763A (en)
KR (1) KR102086788B1 (en)
CN (2) CN105319362B (en)
AU (2) AU2014399919B2 (en)
CA (1) CA2939912C (en)
MY (2) MY195045A (en)
NZ (1) NZ722492A (en)
SG (1) SG11201606106SA (en)
TW (1) TWI700493B (en)
UY (1) UY36200A (en)
WO (1) WO2016003479A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (en) * 2016-09-02 2020-03-17 四川大学 Marker combination for diagnosing liver cancer and application thereof
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (en) 2019-03-13 2020-11-06 충남대학교산학협력단 Biomarker composition comprising TXNDC7 for diagnosis or predicting prognosis of hepatocellular carcinoma
CN110646615B (en) * 2019-08-27 2021-07-13 南方医科大学 Biomarkers, therapeutic targets and uses of liver fibrosis
EP4041888A4 (en) 2019-10-11 2023-11-01 Guardant Health, Inc. Use of cell free bacterial nucleic acids for detection of cancer
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4407042A3 (en) 2020-07-10 2024-09-18 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (en) * 2021-05-27 2021-10-15 深圳市人民医院 Application of reagent for detecting expression level of marker in sample in preparation of kit for detecting or diagnosing breast cancer
CN113777295B (en) * 2021-09-15 2024-03-19 江南大学 Highly sensitive quantum dot probe for detecting tumor marker PD-L1, preparation method and application
CN113956344A (en) * 2021-10-14 2022-01-21 江南大学 Novel FGF analogue for treating liver cancer and application thereof
CN114113611B (en) * 2021-12-13 2023-07-14 郑州大学 A biomarker and detection kit for liver cancer diagnosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) * 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
WO2003058201A2 (en) * 2001-12-31 2003-07-17 Quark Biotech, Inc. Methods for identifying marker genes for cancer
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP3960614B2 (en) * 2003-08-31 2007-08-15 株式会社イムノディア Anti-peptide antibody measurement method and vaccine candidate selection method for peptide vaccine
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
JP2008502891A (en) * 2004-06-18 2008-01-31 エフ．ホフマン−ラ　ロシュ　アーゲー Use of protein PDX1 as a marker for breast cancer
JP5211315B2 (en) * 2006-07-25 2013-06-12 国立大学法人愛媛大学 Tumor marker, tumor diagnostic kit, and method for measuring tumor marker
ES2392312T3 (en) * 2007-08-10 2012-12-07 Hyogo College Of Medicine New liver cancer marker
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (en) * 2010-08-25 2014-05-14 国立大学法人山口大学 Autoantibody detection method
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
WO2013049704A2 (en) 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Also Published As

Publication number Publication date
CN105319362B (en) 2018-07-13
TW201602579A (en) 2016-01-16
KR102086788B1 (en) 2020-03-09
MY179845A (en) 2020-11-18
EP3164711A1 (en) 2017-05-10
HK1248803A1 (en) 2018-10-19
KR20170021234A (en) 2017-02-27
AU2014399919A1 (en) 2016-08-11
JP2020160082A (en) 2020-10-01
CA2939912A1 (en) 2016-01-07
AU2017232129B2 (en) 2018-10-25
CN105319362A (en) 2016-02-10
NZ722492A (en) 2019-09-27
CA2939912C (en) 2019-04-16
CN107478842B (en) 2020-10-16
JP2017520763A (en) 2017-07-27
AU2017232129A1 (en) 2017-10-12
EP3164711A4 (en) 2018-05-23
CN107478842A (en) 2017-12-15
UY36200A (en) 2016-01-29
TWI700493B (en) 2020-08-01
AU2014399919B2 (en) 2019-10-24
SG11201606106SA (en) 2016-08-30
WO2016003479A1 (en) 2016-01-07
HK1224370A1 (en) 2017-08-18

Similar Documents

Publication Publication Date Title
MY195045A (en) Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
WO2015071669A3 (en) Materials and methods for diagnosis and prognosis of liver cancer
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
WO2014140933A8 (en) Method for the prognosis and treatment of cancer metastasis
NZ709167A (en) Compositions and methods for diagnosing thyroid tumors
EP4464797A3 (en) Kit, device, and method for detecting lung cancer
MX2018009304A (en) Diagnostic and prognostic methods for cardiovascular diseases and events.
WO2017062496A3 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
MX2021006791A (en) Methods and compositions for detecting misfolded proteins.
BR112017025297A2 (en) anti-gitr antibodies for cancer diagnosis
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
BR112017003472A2 (en) antibodies, antibody fab fragment and method for treating an inflammatory disease
EP4246144A3 (en) Compositions and methods for screening mutations in thyroid cancer
NZ738875A (en) Motile sperm domain containing protein 2 and cancer
WO2019094780A3 (en) Non-coding rna for detection of cancer
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
EP3869198A3 (en) Reagents and methods for breast cancer detection
SG10201806729VA (en) Novel assay to detect human periostin
NZ729773A (en) Biomarkers for disease progression in melanoma
CY1119430T1 (en) ANTI-S100A7 ANTIBODIES FOR TREATMENT AND CANCER DIAGNOSIS
WO2015169973A3 (en) Marker sequences for diagnosing and stratifying systemic sclerosis patients
WO2016164468A3 (en) Human monoclonal autoantibodies to adamts13 and uses thereof
WO2015166353A3 (en) Early detection of preeclampsia
EP4180814A3 (en) Markers of endometrial cancer